Mads Krogsgaard Thomsen/LinkedIn
Dec 16, 2025, 16:34
Mads Krogsgaard Thomsen on Novo Nordisk Haemophilia Foundation’s Support for Haemoglobinopathies
Mads Krogsgaard Thomsen, CEO at Novo Nordisk Foundation, shared on LinkedIn:
”Haemophilia and other blood disorders like sickle cell disease and thalasaemia are chronic, debilitating diseases.
As is often the case, global health inequity is very pronounced, with under-diagnosis, under-treament and poor outcomes as a result in many low and middle income countries.
It is therefore a pleasure to announce that Novo Nordisk Foundation is stepping up, both in absolute funding terms, and in adding the haemoglobinopathy disorders to our support to the Novo Nordisk Haemophilia and Haemoglobinopathies Foundation in these areas.”
Read the full announcement here.
Stay updated with Hemostasis Today.
-
Mar 16, 2026, 19:16Maha Othman: Delighted to See Our Article Receive The Eberhard F. Mammen Most Popular Article Award 2026
-
Mar 16, 2026, 19:03Limited Evidence for Anticoagulation Despite High VTE Risk in Sickle Cell Disease – RPTH
-
Mar 16, 2026, 18:59Bartosz Hudzik: Choosing The Right Anticoagulant for Acute Venous Thromboembolism
-
Mar 16, 2026, 18:54Michael Recht Appointed Chief Medical and Scientific Advisor to NBDF’s Pathway to Cures
-
Mar 16, 2026, 18:46David McIntosh: Moving Beyond Doubts and Ensuring the Safety of Plasma Donation
-
Mar 16, 2026, 18:42Ramy Abdelnaby: Exploring Advances in Antithrombotic Therapy for Noncardioembolic Ischemic Stroke
-
Mar 16, 2026, 18:27Christina (Tina) P: Help Advance Research and Support Patients with Antiphospholipid Syndrome
-
Mar 16, 2026, 18:20Ahmed Koriesh: Stroke Prevention in the New 2026 ACC/AHA Dyslipidemia Guideline
-
Mar 16, 2026, 18:13Nameer Ascandar: Outcomes After GI Bleeding in Patients with Rheumatoid Arthritis and AF on Long-Term Oral Anticoagulation